HOUSTON, Oct. 29, 2019 /PRNewswire/ -- Moleculin
Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a
clinical stage pharmaceutical company with a broad portfolio of
drug candidates targeting highly resistant tumors, announced the
presentation of a poster at the AACR-NCI-EORTC Molecular Targets
and Cancer Therapeutics Conference today in Boston, MA. The poster, entitled "Dose
and Schedule-Dependent Efficacy of Liposomal Annamycin in
Pre-clinical Models of Acute Myeloid Leukemia," presents data
documenting the high activity of Annamycin against AML, including
in vitro studies in a panel of human AML cell lines, as well as in
vivo studies in both human and murine AML models developed under
the Company's sponsored research agreement with MD Anderson Cancer
Center.
"This study highlights an important new finding," commented
Walter Klemp, Moleculin's Chairman
and CEO. "We've known for some time that Annamycin is
effective in AML animal models and the activity that we believe is
coming from our current AML clinical trials seems to correlate with
this. But, what's new here is the observation that Annamycin
may also be more effective than other drugs due to its high uptake
and effectiveness in eliminating AML cells localized in different
organs. Additional important observations made with these
studies indicates that the long-term exposure of healthy mice (at
least 12 doses so far) to a highly efficacious dose of 4 mg/kg
administered weekly is not toxic and that even two weekly doses of
4 mg/kg are producing a significant increase in survival. And,
because Annamycin is designed to be non-cardiotoxic, this extended
dosing regimen may prove to be feasible and beneficial in
humans. This potentially opens the door for expanded and
improved dosing regimens in future clinical trials."
Quoting from the accepted abstract: "In vivo studies confirmed
anti-tumor efficacy of Annamycin in both human and murine AML
models. Based on bioluminescence imaging, the liposomal formulation
of the drug significantly delayed AML progression in the human
OCL-AML3/NSG model at 4 mg/kg with once weekly dosing. Similarly,
significant dose-dependent reduction of peripheral blood AML blasts
was observed in the murine AML-Turq2 model, and this reduction was
strongly correlated with prolongation of animal survival. The
median survival of mice receiving four doses of L-Ann once a week
at 4 mg/ml was 37 days while mice receiving vehicle lived only 14
days (p=0.0002). Different doses and administration schedules of
[Annamycin] were tested in an effort to maximize survival
benefits. In summary [Annamycin] is effective in AML,
demonstrating significant activity in both in vitro and in vivo
mouse models with a distinct pattern of intracellular uptake and
organ distribution using a once a week schedule. This suggests that
[Annamycin] with this profile, including a lack of cardiotoxicity
and activity against [doxorubicin] resistant tumors, may be an
advantageous approach in the treatment of AML."
To see the entire poster, please go to:
www.moleculin.com
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of oncology
drug candidates for the treatment of highly resistant tumors. The
Company's clinical stage drugs are: Annamycin, a Next Generation
Anthracycline, designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity being studied for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly
referred to as AML, WP1066, an Immune/Transcription Modulator
capable of inhibiting p-STAT3 and other oncogenic transcription
factors while also stimulating a natural immune response, targeting
brain tumors, pancreatic cancer and hematologic malignancies, and
WP1220, an analog to WP1066, for the topical treatment of cutaneous
T-cell lymphoma. Moleculin is also engaged in preclinical
development of additional drug candidates, including additional
Immune/Transcription Modulators, as well as compounds capable of
Metabolism/Glycosylation Inhibition.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Annamycin, with
either the current or modified dosing regimens, to show safety and
efficacy in patients. Although Moleculin believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Moleculin Biotech has attempted to
identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,''
''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors, including those discussed under
Item 1A. "Risk Factors" in our most recently filed Form 10-K filed
with the Securities and Exchange Commission ("SEC") and updated
from time to time in our Form 10-Q filings and in our other public
filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events. The
Company cautions investors not to place undue reliance on the
interim results announced today.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-announces-new-data-confirms-anti-tumor-efficacy-of-annamycin-in-both-human-and-murine-aml-models-300946811.html
SOURCE Moleculin Biotech, Inc.